Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Fiche publication
Date publication
octobre 2019
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Dr VERNEREY Dewi, Pr MANFREDI Sylvain, Mme HENRIQUES Julie
Tous les auteurs :
Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R
Lien Pubmed
Résumé
Patients with wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti-epidermal growth factor receptor (EGFR) combined with first-line, 5-fluorouracil-based chemotherapy. Without the status information, the oncologist can either start chemotherapy with bevacizumab or wait for the introduction of the anti-EGFR. Our objective was to compare both strategies in a routine practice setting.
Mots clés
Anti‐epidermal growth factor receptor, Bevacizumab, Metastatic colorectal cancer, RAS status
Référence
Oncologist. 2019 Oct 2;: